Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors

Gynecologic Oncology

Volumn 108, Issue 1, 2008, Pages 182-190

  Chu, Simon ^a   Alexiadis, Maria ^a   Fuller, Peter J ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

c Abl; c kit; Ovarian cancer; Platelet derived growth factor receptors; Tyrosine kinase

Indexed keywords

ABELSON KINASE; IMATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; STEM CELL FACTOR;

ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GRANULOSA CELL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENES, FMS; GRANULOSA CELL TUMOR; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 37449013816     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.09.017     Document Type: Article

References (36)

1. Schumer S.T., and Cannistra S.A. Granulosa cell tumor of the ovary. J Clin Oncol 21 (2003) 1180-1189
2. Fuller P.J., and Chu S. Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours. Trends Endocrinol Metab 15 (2004) 122-128
3. Chu S., Rushdi S., Zumpe E.T., et al. FSH-regulated gene expression profiles in ovarian tumours and normal ovaries. Mol Hum Reprod 8 (2002) 426-433
4. Kalfa N., Ecochard A., Patte C., Duvillard P., Audran F., Pienkowski C., et al. Activating mutations of the stimulatory G protein in juvenile ovarian granulosa cell tumors: a new prognostic factor?. J Clin Endocrinol Metab 91 (2005) 1842-1847
5. Chu S., Nishi Y., T., Nawata H., and Fuller P.J. Transrepression of estrogen receptor β signalling by nuclear factor-κB in ovarian granulosa cells. Mol Endocrinol 18 (2004) 1919-1928
6. Steinmetz R., Wagoner H.A., Zeng P., Hammond J.R., Hannon T.S., Meyers J.K., et al. Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signalling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol Endocrinol 18 (2004) 2570-2582
7. Capdeville R., Buchdunger E., Zimmermann J., and Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev 1 (2002) 493-502
8. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 (1998) 577-580
9. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., Joensuu H., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 (2003) 4342-4349
10. Druker B.J. Circumventing resistance to kinase-inhibitor therapy. N Eng J Med 354 (2006) 2594-2596
11. Basciani S., Brama M., Mariani S., De Luca G., Arizzi M., Vesci L., et al. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. Cancer Res 65 (2005) 1897-1903
12. Jakob A., Geiger R., and Freidrich WH. Successful treatment of a patient with a granulosa/theca cell tumor of the ovary with STI571 (Gleevec). Proc Am Soc Clin Oncol 21 (2002) (Abstract 1904)
13. Fuller P.J., Chu S., Jobling T., Mamers P., Healy D.L., and Burger H.G. Inhibin subunit gene expression in ovarian cancer. Gynecol Oncol 73 (1999) 273-279
14. Fuller P.J., Zumpe E.T., Chu S., Mamers P., and Burger H.G. Inhibin-activin receptor subunit gene expression in ovarian tumors. J Clin Endocrinol Metab 87 (2002) 1395-1401
15. Chu S., Mamers P., Burger H.G., and Fuller P.J. Estrogen receptor isoform gene expression in ovarian stromal and epithelial tumors. J Clin Endocrinol Metab 85 (2000) 1200-1205
16. Jamieson S., Alexiadis M., and Fuller P.J. Expression status and mutational analysis of the ras and B-raf genes in granulosa cell and epithelial tumors of the ovary. Gynecol Oncol 95 (2005) 603-609
17. Fuller P.J., Alexiadis M., Jobling T., and McNeilage J. Seladin-1/DHCR24 expression in ovarian epithelial and stromal tumours. Clin Endocrinol 63 (2005) 111-115
18. Alexiadis M., Mamers P., Chu S., and Fuller P.J. Insulin-like growth factor, insulin-like growth factor binding protein-4 and pregnancy-associated plasma protein-A gene expression in human granulosa cell tumor. Int J Gynecol Cancer 16 (2006) 1-7
19. Schmandt R.E., Broaddus R., Lu K.H., Shvartsman H., Thornton A., Malpica A., et al. Expression of c-Abl, c-kit and platelet-derived growth factor receptor-β in ovarian serous carcinoma and normal ovarian surface epithelium. Am Cancer Soc (2003) 758-764
20. Wilczynski S.P., Chen Y.-Y., Chen W., Howell S.B., Shively J.E., and Alberts D.S. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRα and PDGFRβ in ovarian cancers. Human Pathol 36 (2005) 242-249
21. Versnel M.A., Haarbrink M., Langerak A.W., de Laat P.A.J.M., Hagemeijer A., van der Kwast T.H., et al. Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo. Cancer Genet Cytogenet 73 (1994) 60-64
22. Chen L.L., Sabripour M., Wu E.F., Prieto V.G., Fuller G.N., and Frazier M.L. A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors. Oncogene 24 (2005) 4271-4280
23. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A., Eisenberg B., Roberts P.J., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Eng J Med 347 (2002) 472-480
24. Crosier P.S., Ricciardi S.T., Hall L.R., Vitas M.R., Clark S.C., and Crosier K.E. Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukaemia. Blood 82 (1993) 1151-1158
25. Zhu W.M., Dong W.F., and Minden M. Alternate splicing creates two forms of the human kit protein. Leuk Lymphoma 12 (1994) 441-447
26. Baselga J., and Arribas J. Treating cancer's kinase 'addiction'. Nat Med 10 (2004) 786-787
27. Zeng P., Wagoner H.A., Pescovitz O.H., and Steinmetz R. RNA interference (RNAi) for extracellular signal-regulated kinase 1 (ERK1) alone is sufficient to suppress cell viability in ovarian cancer cells. Cancer Biol Ther 4 (2005) 961-967
28. Tanikawa M., Harada T., Mitsunari M., Onohara Y., Iwabe T., and Terakawa N. Expression of c-kit messenger ribonucleic acid in human oocyte and presence of soluble c-kit in follicular fluid. J Clin Endocrinol Metab 83 (1998) 1239-1242
29. Ito M., Harada T., Tanikawa M., Fujii A., Shiota G., and Terakawa N. Hepatocyte growth factor and stem cell factor involvement in paracrine interplays of theca and granulosa cells in the human ovary. Fertil Steril 75 (2001) 973-979
30. Yoon S.-J., Kim K.-H., Chung H.-M., Choi D.-H., Lee W.-S., et al. Gene expression profiling of early follicular development in primordial, primary and secondary follicles. Fertil Steril 85 (2006) 193-203
31. Gao B., Lee S.-M., and Fang D. The tyrosine kinase c-Abl protects c-Jun from ubiquitination-mediated degradation in T cells. J Biol Chem 281 (2006) 29711-29718
32. Tanos B., and Pendergast A.M. Abl tyrosine kinase regulates endocytosis of the epidermal growth factor receptor. J Biol Chem 281 (2006) 32714-32723
33. Liu X., Huang W., Li C., Li P., Yuan J., Li X., et al. Interaction between c-Abl and Arg tyrosine kinases and proteasome subunit PSMA7 regulates proteasome degradation. Mol Cell 22 (2006) 317-327
34. Atkins M., Jones C.A., and Kirkpatrick P. Sunitinib maleate. Nat Rev 5 (2006) 279-280
35. Keshava N., Gubba S., and Tekmal R.R. Overexpression of macrophage colony-stimulating factor (CSF-1) and its receptor, c-FMS, in normal ovarian granulosa cells leads to cell proliferation and tumorigenesis. J Soc Gynecol Investig 6 (1999) 41-49
36. Manley P.W., Brüggen J., Fabbro D., Martiny-Baron G., and Meyer T. Extended kinase profiling of the Bcr-Abl inhibitor nilotinib. Abstract No. 3249, AACR Annual Meeting, Los Angeles CA, April 2007 (2007)